Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 27 May 2022, including: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout" - Scrip, 24 May, 2022.)
(Also see "PTC Confident About Commercial Prospects For Gene Therapy Upstaza" - Scrip, 20 May, 2022.)
(Also see "Could CAR-Ts Roll Into The Community Setting?" - Scrip, 25 May, 2022.)
(Also see "Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?" - Scrip, 23 May, 2022.)
(Also see "Russia-Ukraine War Likely To Claim Sputnik V Partners As Casualty" - Scrip, 19 May, 2022.)